Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring

Moderna: Cancer Breakthrough Triggers Share Price Surge

Moderna has made a comeback with a quantum leap. Together with Merck, the biotech company reported positive Phase 3 results for the personalized mRNA cancer therapy Intismeran, when combined with the blockbuster Keytruda. In the study involving 1,137 patients with surgically treated high-risk melanoma, statistically significant and clinically relevant improvements were achieved compared to Keytruda alone in both recurrence-free survival and the occurrence of distant metastases.

What makes this approach unique is its individualization. A customized mRNA therapy is produced for each patient based on the
tumor’s genetic characteristics. This is intended to help the immune system recognize characteristic tumor mutations and target cancer cells more precisely.

This could mark the beginning of a new era for Moderna. Following the end of the COVID-19 boom, the company was urgently seeking a new growth driver. Intismeran could be exactly that. The stock market reacted with euphoria, sending the share price up by as much as 160% and increasing Moderna’s market capitalization by USD 40 billion.

Even more important is the potential beyond skin cancer. Moderna and Merck are already investigating the technology for other types of tumors. If the approach proves successful there, the study’s success could give rise to a new platform for cancer medicine.

Vidac Pharma: European Expansion Opens New Opportunities

While Moderna activates the immune system with a personalized mRNA therapy, Vidac Pharma is pursuing a completely different approach and vigorously driving its expansion in Europe. Its planned French subsidiary, Eutopos Pharma, was selected for Quest for Health, one of Europe’s leading innovation accelerators for healthcare and life sciences. This gives the biotech company access to a network of pharmaceutical companies, research institutions, clinics, and investors—and positions it at the heart of the cross-border BioValley ecosystem spanning France, Germany and Switzerland.

Vidac is pursuing a novel approach to cancer therapy. Rather than primarily activating the immune system, the drug candidates target the altered energy metabolism of cancer cells. The most advanced candidate, Tuvatexib (VDA-1102), is currently in a Phase 2b trial for high-risk actinic keratosis. All 39 patients have now been enrolled. With VDA-1275, Vidac is also developing a candidate for the treatment of solid tumors.

Eutopos could become a key building block, particularly for further development. The new company is set to be established in Strasbourg as a European platform for research, clinical trials, business development, partnerships and licensing. Dr. Séverine Sigrist, an experienced biotech entrepreneur, will take over operational leadership.

Being accepted into Quest for Health could significantly accelerate this expansion. The accelerator currently supports 60 health tech startups and is networked through ten partners in France, Germany, Switzerland and Belgium. This opens up new opportunities for Vidac to advance clinical programs, attract investors, and initiate collaborations with larger pharmaceutical companies.

If Vidac’s metabolic approach delivers convincing clinical data, the combination of innovative technology and a growing European infrastructure could lay the groundwork for licensing deals, strategic partnerships, and significantly faster commercialization. For the still-small biotech company, Eutopos could thus become far more than just a new subsidiary—namely, the springboard into the European pharmaceutical market.

Merck: Keytruda Gets Its Next Billion-Dollar Opportunity

For Merck, the Phase 3 success is at least as significant as it is for its partner Moderna. With Keytruda, the pharmaceutical giant already has one of the industry’s biggest blockbusters. In the second quarter of 2026 alone, revenue from Keytruda and Keytruda Qlex reached USD 8.4 billion, an increase of 5%. The entire group generated USD 16.6 billion in revenue.

Now, the combination with Intismeran opens up new possibilities. Instead of simply maximizing Keytruda’s potential as an existing cancer drug, Merck could make the active ingredient the backbone of a new generation of personalized combination therapies.

The Phase 3 data for high-risk melanoma provide the decisive evidence for this for the first time. The potential for applying this approach to other types of cancer is enormous. The companies are investigating this approach in lung, bladder, and kidney cancer, among others. Overall, an extensive clinical development program is underway.

The stakes are high for Merck. Keytruda is the financial backbone of the company. New combinations could not only generate additional billions in revenue but also extend the significance of the Keytruda platform for years to come.

Complete Phase 3 data and robust results are still pending. However, the success of the past trading week has cleared a major hurdle. Should Intismeran also prove effective against other types of tumors, Merck, together with Moderna, could tap into a new billion-dollar market.

With the positive Phase 3 data for Intismeran, Moderna has the opportunity to tap into a new billion-dollar market with personalized cancer therapies following the COVID-19 boom. Vidac Pharma, on the other hand, targets the energy metabolism of cancer cells and could significantly accelerate its European expansion with Eutopos, Quest for Health, and its ongoing clinical programs. By combining Keytruda and Intismeran, Merck has the opportunity to build on its most important blockbuster to create the foundation for a new generation of personalized cancer therapies.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.